{"entity":{"id":"gercor","kind":"company","name":"GERCOR","aka":["GERCOR - Multidisciplinary Oncology Cooperative Group","Groupe Coopérateur Multidisciplinaire en Oncologie"],"tldr":"GERCOR is a French non-profit cooperative group created in 1997 that sponsors its own phase 2 and 3 solid tumour trials through a network of about 300 investigators; in OnCo it leads LAP07 in locally advanced pancreatic cancer.","summary":"GERCOR was created in 1997 as a non-profit entity whose mission is to improve treatment for patients with solid tumours through innovative multidisciplinary clinical research; it sponsors phase 2 and phase 3 trials independently and draws on a national network of 300 members in about a hundred centres, from an office at 151 rue du Faubourg Saint-Antoine, Paris (gercor.com). ClinicalTrials.gov registers it as GERCOR - Multidisciplinary Oncology Cooperative Group (OTHER class) and names it lead sponsor of LAP07 (NCT00634725, phase 3, chemoradiotherapy against chemotherapy alone after induction in locally advanced pancreatic cancer), the trial recorded in OnCo. It has no products of its own.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.gercor.com"},{"label":"ClinicalTrials.gov: trials led by GERCOR - Multidisciplinary Oncology Cooperative Group","url":"https://clinicaltrials.gov/search?lead=GERCOR%20-%20Multidisciplinary%20Oncology%20Cooperative%20Group"}],"tags":["ctgov-sponsor","cooperative-group"],"related":[],"cancers":["pancreatic","locally-advanced-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["lap07"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo cooperative groups round (group websites, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-25"},"hq":"Paris","country":"FR","companyType":"cooperative-group","website":"https://www.gercor.com","founded":1997,"investors":[],"funding":[]},"route":"/companies/gercor/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"trial":[{"id":"nct07071844","kind":"trial","name":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","route":"/trials/nct07071844/"},{"id":"lap07","kind":"trial","name":"LAP07","route":"/trials/lap07/"},{"id":"nct06646445","kind":"trial","name":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.","route":"/trials/nct06646445/"},{"id":"nct05310643","kind":"trial","name":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","route":"/trials/nct05310643/"},{"id":"nct07028424","kind":"trial","name":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","route":"/trials/nct07028424/"},{"id":"nct03828227","kind":"trial","name":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","route":"/trials/nct03828227/"}]}}